Exopharm has been granted the exclusive world-wide right to use the LEAP technology to produce bioactive packages secreted by stem cells that can be thought of as virtual stem cells:
Exomeres - the stem cell alternative.
Stem cells showed promise but ...
Our bodies rely upon cells self-renewing to grow and then later to replace damaged or old cells. Usually the body is pretty good at this, but sometimes it needs help, especially as we age and systems of renewal become less effective.
Injecting large numbers of stem cells into patients once seemed like a sensible way to replace cells, but many years of clinical trials have shown that using stem cells themselves as a medicine has many problems, including safety, cost, manufacturing, and having to freeze them for transport and storage then carefully thaw them for use. Stem cell therapy is complex and unwieldy, a bit like the internet before Google. What we need is a more practical way to harness the power of stem cells, but without their problems.
The potential solution – Exomeres are virtual stem cells
Researchers have recently discovered that whole stem cells may not be needed for regenerative purposes – just the key active part secreted by the stem cells. It’s a bit like progressing from willow bark to the aspirin pill or finding that it’s the chocolate chip and not the cookie that makes you happy.
There is growing evidence that bioactive packages secreted by stem cells (we call them Exomeres) are the key means by which that injected stem cells can drive regeneration and healing in patients; and that using the Exomeres themselves could overcome the limitations of whole stem cells.
This advance has major implications for advancing regenerative medicine - but unfortunately, the efficient separation of Exomeres has proven to be very difficult indeed. Until now.
The technology being converted into an international company
Dr. Ian Dixon, a biomedical engineer, has spent three years to overcome this problem and recently had a ‘lightbulb’ moment. He has invented a simple yet efficient method called LEAP that will extract pharmaceutical-grade exomeres from cells in a fraction of the time taken by conventional methods, and cost less, too.
Exomeres are expected to treat conditions such as osteoporosis, asthma, fibrosis, wound healing, cardiac repair, sport injuries and neurodegeneration.
Exopharm is now building partnerships in USA, China and Europe and plans to establish manufacturing plants to make Exomere products in large scale. Clinical trials with Exomeres are due to start in 2018 and Exopharm aims to list on the Australian Stock Exchange.